SCHEMBL801800

SCHEMBL801800

Cc1nc(Nc2nc(-c3ccccc3C(F)(F)F)nc3c2CCCCC3)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
CYP1A2 P05177 5/20 0.39
CYP2C19 P33261 5/20 0.39
CYP2D6 P10635 4/20 0.39
RECQL P46063 1/20 0.39
USP1 O94782 8/20 0.38
WDR48 Q8TAF3 8/20 0.38
TRPV1 Q8NER1 3/20 0.37
IGF1R P08069 1/20 0.37
TRPA1 O75762 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
CYP3A4 P08684 3/20 0.37
MEN1 O00255 2/20 0.37
TSHR P16473 2/20 0.37
KMT2A Q03164 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CLK4 Q9HAZ1 1/20 0.37
VCP P55072 1/20 0.37
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801759 0.99 GSK3A (0.41) GSK3AGSK3BCYP1A2CYP2C19CYP2D6
SCHEMBL801822 0.97 GSK3A (0.41) GSK3AGSK3BCYP1A2CYP2C19CYP2D6
SCHEMBL802433 0.89 USP1 (0.39) CYP1A2CYP2C19CYP2D6RECQLUSP1
SCHEMBL805607 0.87 GSK3A (0.45) GSK3AGSK3BCYP1A2CYP2C19CYP2D6
SCHEMBL14164022 0.86 USP1 (0.39) CYP1A2CYP2C19CYP2D6RECQLUSP1
SCHEMBL802471 0.85 IGF1R (0.43) CYP1A2CYP2C19CYP2D6RECQLUSP1
SCHEMBL802172 0.85 IGF1R (0.43) CYP1A2CYP2C19CYP2D6RECQLUSP1
SCHEMBL805635 0.85 GSK3A (0.38) GSK3AGSK3BCYP1A2CYP2C19CYP2D6
SCHEMBL802429 0.85 GSK3A (0.42) GSK3AGSK3BCYP1A2CYP2C19CYP2D6
SCHEMBL802430 0.84 IGF1R (0.44) CYP1A2CYP2C19CYP2D6RECQLUSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885CYP1A2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.